{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T12:18:47Z","timestamp":1764937127362,"version":"build-2065373602"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,11,5]],"date-time":"2019-11-05T00:00:00Z","timestamp":1572912000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.ejca.2019.10.010","type":"journal-article","created":{"date-parts":[[2019,11,22]],"date-time":"2019-11-22T12:28:47Z","timestamp":1574425727000},"page":"131-141","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Dual Erb B Inhibition in Oesophago-gastric Cancer (DEBIOC): A phase I dose escalating safety study and randomised dose expansion of AZD8931 in combination with oxaliplatin and capecitabine chemotherapy in patients with oesophagogastric adenocarcinoma"],"prefix":"10.1016","volume":"124","author":[{"given":"Anne","family":"Thomas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pradeep S.","family":"Virdee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Eatock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon R.","family":"Lord","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Falk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D. Alan","family":"Anthoney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard C.","family":"Turkington","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Goff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leena","family":"Elhussein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda","family":"Collins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharon","family":"Love","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanna","family":"Moschandreas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark R.","family":"Middleton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2019.10.010_bib1","unstructured":"CRUK. Cancer Statistics. https:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/: [CRUK] ."},{"key":"10.1016\/j.ejca.2019.10.010_bib2","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1038\/s41416-018-0047-4","article-title":"Trends and projections in adenocarcinoma and squamous cell carcinoma of the oesophagus in England from 1971 to 2037","volume":"118","author":"Offman","year":"2018","journal-title":"Br J Canc"},{"issue":"Suppl 3","key":"10.1016\/j.ejca.2019.10.010_bib3","first-page":"S289","article-title":"Esophageal cancer: staging system and guidelines for staging and treatment","volume":"6","author":"Berry","year":"2014","journal-title":"J Thorac Dis"},{"year":"2018","series-title":"National Oesophago-gastric cancer audit","key":"10.1016\/j.ejca.2019.10.010_bib4"},{"key":"10.1016\/j.ejca.2019.10.010_bib5","doi-asserted-by":"crossref","first-page":"5062","DOI":"10.1200\/JCO.2009.22.2083","article-title":"Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer","volume":"27","author":"Allum","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2019.10.010_bib6","doi-asserted-by":"crossref","first-page":"4004","DOI":"10.1200\/JCO.2017.35.15_suppl.4004","volume":"35","author":"Al-Batran","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2019.10.010_bib7","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1200\/JCO.2010.33.0597","article-title":"Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial","volume":"29","author":"Ychou","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2019.10.010_bib8","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa055531","article-title":"Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer","volume":"355","author":"Cunningham","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2019.10.010_bib9","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1200\/JCO.2017.73.7718","article-title":"Effect of neoadjuvant chemoradiotherapy on health-related quality of life in esophageal or junctional cancer: results from the randomized CROSS trial","volume":"36","author":"Noordman","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2019.10.010_bib10","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/S1470-2045(17)30447-3","article-title":"Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with oesophageal adenocarcinoma (UK MRC OE05): an open-label, randomised phase 3 trial","volume":"18","author":"Alderson","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2019.10.010_bib11","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S1470-2045(17)30043-8","article-title":"Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2-3 trial","volume":"18","author":"Cunningham","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2019.10.010_bib12","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/nrclinonc.2011.45","article-title":"Targeting the human EGFR family in esophagogastric cancer","volume":"8","author":"Okines","year":"2011","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ejca.2019.10.010_bib13","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2019.10.010_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/jco.2013.31.15_suppl.4098","article-title":"NeoHx study: perioperative treatment with trastuzumab in combination with capecitabine and oxaliplatin (XELOX-T) in patients with HER2 resectable stomach or esophagogastric junction (EGJ) adenocarcinoma\u2014R0 resection, pCR, and toxicity analysis","volume":"31","author":"Rivera","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2019.10.010_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/jco.2014.32.15_suppl.4073","article-title":"HER-FLOT: trastuzumab in combination with FLOT as perioperative treatment for patients with HER2-positive locally advanced esophagogastric adenocarcinoma: a phase II trial of the AIO Gastric Cancer Study Group","volume":"32","author":"Hofheinz","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2019.10.010_bib16","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1002\/ijc.28771","article-title":"EGFR, HER2 and HER3 dimerization patterns guide targeted inhibition in two histotypes of esophageal cancer","volume":"135","author":"Fichter","year":"2014","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ejca.2019.10.010_bib17","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1002\/cncr.28435","article-title":"HER-2\/neu gene amplification in relation to expression of HER2 and HER3 proteins in patients with esophageal adenocarcinoma","volume":"120","author":"Yoon","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2019.10.010_bib18","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1158\/1078-0432.CCR-09-2353","article-title":"AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor, ERBB2 (HER2), and ERBB3: a unique agent for simultaneous ERBB receptor blockade in cancer","volume":"16","author":"Hickinson","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2019.10.010_bib19","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1200\/JCO.2007.12.7712","article-title":"Shortening the timeline of pediatric phase I trials: the rolling six design","volume":"26","author":"Skolnik","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2019.10.010_bib20","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1200\/JCO.1991.9.1.191","article-title":"Median follow-up in clinical trials","volume":"9","author":"Shuster","year":"1991","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2019.10.010_bib21","first-page":"169","article-title":"Analysis Working Group: asan U, Agency BCC, Brigham, Women's H, Broad I, et\u00a0al. Integrated genomic characterization of oesophageal carcinoma","volume":"541","author":"Cancer Genome Atlas Research","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.ejca.2019.10.010_bib22","first-page":"493","article-title":"EGFR, HER2 and HER3 expression in esophageal primary tumours and corresponding metastases","volume":"31","author":"Wei","year":"2007","journal-title":"Int J Oncol"},{"key":"10.1016\/j.ejca.2019.10.010_bib23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0161781","article-title":"HER3 expression is a marker of tumor progression in premalignant lesions of the gastroesophageal junction","volume":"11","author":"Ecker","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.ejca.2019.10.010_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pharmthera.2014.01.005","article-title":"HER3, serious partner in crime: therapeutic approaches and potential biomarkers for effect of HER3-targeting","volume":"143","author":"Kol","year":"2014","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.ejca.2019.10.010_bib25","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1021\/ml400146c","article-title":"Discovery of AZD8931, an equipotent, reversible inhibitor of signaling by EGFR, HER2, and HER3 receptors","volume":"4","author":"Barlaam","year":"2013","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.ejca.2019.10.010_bib26","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s10637-013-9963-6","article-title":"Phase I, dose-finding study of AZD8931, an inhibitor of EGFR (erbB1), HER2 (erbB2) and HER3 (erbB3) signaling, in patients with advanced solid tumors","volume":"32","author":"Tjulandin","year":"2014","journal-title":"Investig New Drugs"},{"key":"10.1016\/j.ejca.2019.10.010_bib27","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S2468-1253(17)30394-1","article-title":"Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2-3 randomised trial","volume":"3","author":"Adams","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.ejca.2019.10.010_bib28","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s10549-016-3979-5","article-title":"Inhibition of EGFR, HER2, and HER3 signaling with AZD8931 in combination with anastrozole as an anticancer approach: phase II randomized study in women with endocrine-therapy-naive advanced breast cancer","volume":"160","author":"Johnston","year":"2016","journal-title":"Breast Canc Res Treat"},{"key":"10.1016\/j.ejca.2019.10.010_bib29","first-page":"85","article-title":"Dermatologic toxicity occurring during anti-EGFR monoclonal inhibitor therapy in patients with metastatic colorectal cancer: a systematic review","volume":"17","author":"Lacouture","year":"2018","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.ejca.2019.10.010_bib30","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1200\/JCO.2016.70.3934","article-title":"Gefitinib and EGFR gene copy number aberrations in esophageal cancer","volume":"35","author":"Petty","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2019.10.010_bib31","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S1470-2045(07)70039-6","article-title":"Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis","volume":"8","author":"Gebski","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2019.10.010_bib32","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1016\/S0140-6736(02)08651-8","article-title":"Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial","volume":"359","author":"Medical Research Council Oesophageal Cancer Working","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2019.10.010_bib33","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1007\/s12032-011-0001-2","article-title":"Neoadjuvant concurrent chemoradiotherapy with capecitabine and oxaliplatin in patients with locally advanced esophegeal cancer","volume":"29","author":"Wahba","year":"2012","journal-title":"Med Oncol"},{"key":"10.1016\/j.ejca.2019.10.010_bib34","doi-asserted-by":"crossref","first-page":"5210","DOI":"10.1200\/JCO.2009.26.6114","article-title":"Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954","volume":"28","author":"Schuhmacher","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2019.10.010_bib35","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.bpg.2018.11.005","article-title":"Chemotherapy and novel targeted therapies for operable esophageal and gastroesophageal junctional cancer","volume":"36\u201337","author":"van den Ende","year":"2018","journal-title":"Best Pract Res Clin Gastroenterol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804919307737?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804919307737?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:26:36Z","timestamp":1760732796000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804919307737"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":35,"alternative-id":["S0959804919307737"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2019.10.010","relation":{},"ISSN":["0959-8049"],"issn-type":[{"type":"print","value":"0959-8049"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dual Erb B Inhibition in Oesophago-gastric Cancer (DEBIOC): A phase I dose escalating safety study and randomised dose expansion of AZD8931 in combination with oxaliplatin and capecitabine chemotherapy in patients with oesophagogastric adenocarcinoma","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2019.10.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}